Startups
Edit

ZAKA

https://zaka.vc/
Last activity: 28.07.2026
Active
We back pre-seed companies using purely private money and actively help them make a mark.
Mentions
45

Mentions in press and media 45

DateTitleDescription
Sign up to seeSign up to seeSign up to see
May 7, 2026ParcelBio Raises $13M in Seed FundingParcelBio, a San Francisco, CA-based biotechnology company developing a new class of potent and durable mRNA medicines, raised $13M in Seed funding. The round was led by Breyer Capital, with participation from General Catalyst, Y Combinator...
May 7, 2026ParcelBio: $13 Million Seed Financing Raised To Advance Next-Generation mRNA MedicinesParcelBio launched with $13 million in seed financing led by Breyer Capital, with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC, and additional investors. The company said the financing will supp...
Feb 26, 2026ZAKA VC Joins Cirrus Therapeutics’ Seed Round, Transforming Vision Care with Next-Gen Gene TherapyZAKA VC backs Cirrus Therapeutics’ gene therapies for chronic blinding eye diseases, focusing on dry AMD The startup’s IRAK-M therapy targets upstream aging biology, restoring immune balance in the retina The new funding accelerates Cirrus ...
Feb 16, 2026ZAKA VC Backs DeepSeq.AI’s Functional Approach to Protein Drug DiscoveryZAKA VC backs DeepSeq.AI’s hyperscaled functional data application for AI-driven protein drug discovery The founding team combines AI innovation, biological screening, and commercial biotech leadership The platform focuses on function, not ...
Jan 9, 2026When AI Enters the Operating Room: AceON Accelerator Backs JST 3D’s AI Vision for the Future of SurgeryAceON Accelerator selected JST 3D as the winning solution among its highly competitive 5th cohort JST 3D uses AI to transform CT scans into high-precision interactive 3D models The technology improves surgical planning by revealing anatomic...
Jan 7, 2026Zaka VC Invests in DeepSeq.AI to Transform AI-Based Protein Drug DiscoveryTransforming AI-Based Protein Drug Discovery Using HyperScaled Data The team brings a strong balance of scientific and commercial expertise, has built a unique data foundation with a compelling moat, and has already demonstrated promising e...
Nov 28, 2025ZAKA VC Backs Nephrogen’s Kidney-Focused Gene Therapy PlatformZAKA VC supports Nephrogen, a gene therapy startup for kidney and pancreas diseases The founder is motivated by personal health experience to develop a cure Nephrogen’s NeFIND™ platform enables precise, efficient, and scalable gene therapy ...
Nov 27, 2025Mews and Flexkeeping Unite for Operational Excellence at Smarter, Connected HotelsMews acquired Flexkeeping, deepening their years-long partnership to enhance hotel operations The integration adds advanced housekeeping automation to Mews’ growing end-to-end hospitality ecosystem Joining forces, the platforms boost effici...
Aug 6, 2025AceON Accelerator Comes Back This Autumn for More Startup Success StoriesAceON Accelerator´s upcoming program will be two-months-long and fully online, starting on October 2nd, designed to help idea-stage and pre-seed startups across Europe grow fast. Open to founders from any industry, the program offers hands-...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about ZAKA

What has the press written about ZAKA?

Parsers VC has collected 45 articles mentioning ZAKA, among them “ParcelBio Raises $13M in Seed Funding” (May 7, 2026) and “ParcelBio: $13 Million Seed Financing Raised To Advance Next-Generation mRNA Medicines” (May 7, 2026).

Is ZAKA still active?

Yes, ZAKA is active; its latest activity on Parsers VC dates from Jul 28, 2026.